BIOexpress
Biotronik, Inc. · Decision date Oct 16, 2026
What did the FDA approve?
The FDA record shows approval of supplement P070008/S177 for BIOexpress, filed by Biotronik, Inc. under the normal 180-day track. The stated reason is a change to design, components, specifications or material. The approved statement describes BIOexpress as a dedicated interrogation-only device for status checks of BIOTRONIK implantable pulse generators (IPGs, CRT-Ps), implantable cardioverter defibrillators (ICDs, CRT-Ds) and implantable cardiac monitors (ICMs).
The S177 designation ties this action to the original P070008 approval, but a supplement is not a new approval of the whole system. The record does not specify what the changed design item is beyond the general category, and the statement's purpose language does not by itself establish safety or clinical effectiveness. One detail is absent: the record does not identify which BIOexpress component or specification changed.
The device category listed is a pulse generator, pacemaker, implantable, with cardiac resynchronization (CRT-P), product code NKE, cardiovascular specialty.
FDA approval order statement
BIOexpress, a dedicated interrogation-only device for status checks of BIOTRONIK implantable pulse generators (IPGs, CRT-Ps), implantable cardioverter defibrillators (ICDs, CRT-Ds) and implantable cardiac monitors (ICMs)
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 16, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P070008/S177
- Regulatory pathway
- PMA supplement
- Applicant
- Biotronik, Inc.
- Product code
- NKE
- Decision code
- APPR
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Pulse generator, pacemaker, implantable, with cardiac resynchronization (CRT-P).
- Applicant
- Biotronik, Inc.
- Product code
- NKE
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P070008. Subsequent supplements may change the device or its indications.
FDA decision timeline
P070008 · Original PMA
STRATOS LV CRT-P AND STRATOS LV-T CRT-P, COROX OTW BP LEAD AND COROX OTW-S BP LEAD
P070008/S177 received
Application receipt date recorded by FDA.
P070008/S179 · Related supplement
PSW 2601.U, NEO 2601.U
P070008/S172 · Related supplement
Edora 8 HF-T QP 407137 Edora 8 HF-T 407138 Evity 8 HF-T QP 407139 Evity 8 HF-T 407140 Enitra 8 HF-T QP 407141 Enitra 8 H
P070008/S182 · Related supplement
Edora 8 HF-T QP Edora 8 HF-T Evity 8 HF-T QP Evity 8 HF-T Enitra 8 HF-T QP Enitra 8 HF-T Enticos 8 HF-T QP Enticos 8 HF-
P070008/S181 · Related supplement
Edora 8 HF-T QP 407137; Edora 8 HF-T 407138; Evity 8 HF-T QP 407139; Evity 8 HF-T 407140; Enitra 8 HF-T QP 407141; Enitr
P070008/S183 · Related supplement
Edora 8 HF-T QP, Edora 8 HF-T, Evity 8 HF-T QP, Evity 8 HF-T, Enitra 8 HF-T QP, Enitra 8 HF-T
P070008/S177 · FDA decision
Normal 180 Day Track
P070008/S184 · Related supplement
Sentus ProMRI OTW QP S-75, Sentus ProMRI OTW QP S-85, Sentus ProMRI OTW QP S-95, Sentus ProMRI OTW QP L-75, Sentus ProMR
Timeline entries are records held by MedtechLedger for P070008. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P070008
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA approval | May 12, 2008 | FDA | |
PSW 2601.U, NEO 2601.UP070008/S179 | Biotronik, Inc. | PMA supplement | Sep 17, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 5, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA |
Explore the linked device profile
Other records with product code NKE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Guidant Corp. | PMA supplement | Oct 3, 2026 | FDA | |
| Guidant Corp. | PMA approval | Jan 26, 2004 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6024 Jean Rd., Lake Oswego, OR, 97035
Sources and methodology
- Original FDA record: P070008/S177
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


